

Filter protection in carotid artery stenting: consider limited protection

Jakub Chmiel^{1,2,3}, Lukasz Tekieli^{1,2,4}, Adam Mazurek^{1,2}, Lukasz Czyz^{1,2}, Piotr Musialek^{1,2}

¹Department of Cardiac and Vascular Diseases, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland

²St. John Paul II Hospital, Krakow, Poland

³Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, Krakow, Poland

⁴Department of Interventional Cardiology, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland

Adv Interv Cardiol 2024; 20, 2 (76): 213–216
DOI: <https://doi.org/10.5114/aic.2024.140842>

Strokes in mechanistic relation to carotid atherosclerosis are often large and disabling [1]. Evidence shows that pharmacologic therapy (even if maximised) is not sufficient to universally prevent carotid-related strokes [2]. Revascularisation continues to play an important role in particular in increased-stroke-risk carotid lesions [2, 3], with carotid artery stenting (CAS) as a minimally invasive technique in primary and secondary prevention of carotid-related stroke [2, 3].

Carotid atherothrombotic plaques are often fragile; thus, any plaque manipulation generates embolic material. Both CAS and carotid surgery are (and will remain) embologenic [4]. Unprotected CAS carries the risk of cerebral embolism at each of the key stages of the procedure, from the lesion crossing with a wire, through stenosis predilatation, stent positioning and implantation, and stent post-dilatation [5]. Several cerebral embolic protection strategies have been developed to improve the safety of CAS, including distal filter devices and transient flow arrest/reversal devices [5].

Filter use is associated with “unprotected” crossing of the lesion and other limitations such as risk of suboptimal filter apposition to the arterial wall, embolism with particles smaller than the filter pores (~100–180 µm) and limited filter basket capacity [5]. However, filter use is intuitive, it allows maintained visualisation throughout the procedure, and it remains to be the preferred mode of embolic protection by majority of CAS operators [6]. In the case presented (Figure 1), when discussing the procedure strategy in the context of clinical presentation, baseline ultrasound imaging examination and baseline angiogram (LINC – Leipzig Interventional Course 2024; Session “20 years of innovation: Best practice in carotid revascularization”;

P. Musialek: Carotid revascularisation in 2024: Key factors to consider), the majority of operators declared a preference for using a filter protection. The results of the poll were the following: CAS with filter protection – 76.2%, CAS with proximal system – 6.3%, surgery – 5.3%, pharmacological treatment only – 1.1%, no clear preference – 11.1%.

Proximal protection, in comparison with filter protection, reduces the magnitude of cerebral embolism by ≈10- to 30-fold at the stages of lesion wiring, predilatation, stent positioning and deployment, and stent post-dilatation [7]. Proximal embolic protection is associated not only with a lower incidence and magnitude of procedural cerebral microembolisation but also with a lower incidence of cerebral adverse events [8]. Proximal systems, if appropriately used, allow zero intraprocedural cerebral embolism [9], but they are less intuitive and require training for a competent application [5, 9, 10]. Recent analysis from the ACST-2 trial showed filter use in 80% protected CAS procedures (proximal devices – 20%, including mostly the Mo.Ma system) [6]. Proximal embolic protection requires operator familiarity with the system and proficiency in its application, including a learning curve. This is compensated with the proximal protection capacity to capture debris of all sizes from the point of lesion crossing to the point of stent postdilatation optimisation.

We demonstrate a very rare but serious cerebral embolic complication that occurred with filter protection use in absence of on-shelf availability of the Mo.Ma system [5, 7]. In the presented case, multi-focal cerebral iatrogenic embolism was not amenable to mechanical intervention (distal-vessel occlusions) – as primarily non-thrombotic – and it did not respond to administration of 10 mg rtPA via the distal internal carotid artery (Figure 1).

Corresponding author:

Jakub Chmiel, Department of Cardiac and Vascular Diseases, Institute of Cardiology, Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, St. John Paul II Hospital, Krakow, Poland, phone: +48 793 683 723, e-mail: jakubandrzejchmiel@gmail.com

Received: 13.06.2024, **accepted:** 17.06.2024, **online publication:** 30.06.2024.




Figure 1. Filter-protected CAS demonstrating limitations of filter protection despite anti-embolic stent use. A 59-year-old man was admitted for carotid revascularisation 2 weeks after left-hemispheric TIA. (Cont'd on next page)

Duplex Doppler ultrasound examination showed a fibro-lipidic atherosclerotic plaque in LICA causing a significant stenosis (A). LCCA/LICA angiogram showed a significant LICA stenosis with a visible contrast channel (B). Baseline left cerebral angiogram is shown in C. In absence of Mo.Ma proximal protection on-shelf availability a decision was made to use a distal (filter) cerebral protection and an (routine) anti-embolic stent. The filter was uneventfully delivered through the lesion and was opened in distal LICA (D – white arrowhead). A gentle predilatation was performed with a small coronary balloon (E). There was an acute deterioration of the patient neurologic status with impairment of responsiveness. An anti-embolic stent was implanted (F) and routinely optimised (G). However, “no flow” was visible in the treated artery upon contrast injection (H), consistent with filter blockage by embolic material. Acute neurologic symptoms of left cerebral hemispheric ischaemia were aggravating. To minimise the risk of distal embolism, the filter was removed in a “half-open” position (I). The filter examination showed macroscopic evidence of embolic material (J). Carotid completion angiogram (K) demonstrated an optimal angiographic result at the level of carotid bifurcation. Cerebral angiogram (L) demonstrated multiple distal cerebral artery embolic lesions as well as embolism of the anterior communicating artery (red arrowheads). The latter, however, had a good compensatory filling from the contralateral (right) side; thus, no anterior communicating artery thrombectomy was considered indicated. RtPA (10 mg) was administered to distal LICA via a microcatheter (M), but no symptom improvement (and no cerebral angiogram improvement) occurred over 45 min, consistent with athero-embolic rather than thrombo-embolic mechanism of the multiple distal vessel occlusion. The patient developed a multi-site left hemispheric infarct (N, M – black arrowheads) with clinical symptoms of an acute procedure-related stroke. Discharge mRS (day 9) was 3. On clinical examination at 90-days the patient had residual neurologic deficit but was functionally independent (mRS 2). There were permanent multi-site chronic infarcts on cerebral plain CT (R) that corresponded to the (sub)acute cerebral lesions depicted in P.

Note that filter use in endovascular carotid revascularisation may be associated with distal embolism risk due to (1) unprotected crossing of the lesion, (2) potential filter basket malapposition, (3) embolism by particles < filter pore size, and (4) limited filter basket capacity [5]. On the other hand, the anti-embolic stent cerebral protection is exerted only after the stent full deployment and optimisation – but it then extends throughout the stent healing period. These filter limitations do not apply to proximal protection by transient flow cessation or reversal [5, 7, 9, 15]

CT – computed tomography, *mRS* – modified Rankin scale, *LCCA* – left common carotid artery, *LICA* – left internal carotid artery, *TIA* – transient ischaemic attack.

In the case presented, the MicroNET-covered anti-embolic stent was selected to extend neuroprotection throughout the period of stent healing. This second-generation carotid stent has sealing properties [11–14] and level-1 evidence for a significant reduction of intra-procedural plaque-related cerebral embolism and elimination of post-procedural ischaemic events. It is important to note that the anti-embolic stent will exert its cerebral embolism prevention only from the point of its implantation and full optimisation [5]. Proximal/distal protective devices and anti-embolic stents play complementary roles in cerebral protection and cannot be replaced by each other, and they are not to be used interchangeably [5, 10, 15].

In conclusion, the role of embolic protection devices is maintained in the era of anti-embolic stent use. There remains a need to take advantage of the unique features of proximal embolic protection systems (including their potential to completely prevent cerebral ischaemic events) [5, 7, 9, 10], particularly when treating lesions of increased embolic risk. CAS operators should be cognisant of the fact that the anti-embolic stent cannot be expected to exert any effect until implanted and post-dilated [15]. Practical knowledge and experience on

how to use proximal cerebral protection to reduce intra-procedural embolic complications of CAS is an indispensable element of today’s competent CAS [5, 7].

Ethical approval

Not applicable.

Funding

The study was supported by the Jagiellonian University Medical College (N41/DBS/001103) and Polish Cardiac Society/Servier grant for Clinical Research in Carotid Atherosclerosis (to PM). It was also supported by the National Committee for Scientific Research (2022/06/X/NZ5/00583, 2023/07/X/NZ5/00256).

Conflict of interest

PM has proctored and/or consulted for Abbott Vascular, Balton, Gore, InspireMD, and Medtronic; he has served as the Polish Cardiac Society Board Representative for Stroke and Vascular Interventions and serves on the ESC Stroke Council Scientific Documents Task Force. PM is Co-PI of the CGuardians FDA IDE Trial. Other authors declare no conflict of interest.

References

1. Tekieli L, Dzierwa K, Grunwald IQ, et al. Outcomes in acute carotid-related stroke eligible for mechanical reperfusion: SAFE-GUARD-STROKE Registry. *J Cardiovasc Surg* 2024 [in press].
2. Musialek P, Bonati LH, Bulbulia R, et al. Stroke risk management in carotid atherosclerotic disease: a Clinical Consensus Statement of the ESC Council on Stroke and the ESC Working Group on Aorta and Peripheral Vascular Diseases. *Cardiovasc Res* 2023 Aug 25;cvad135. doi: 10.1093/cvr/cvad135.
3. Musialek P, Rosenfield K, Siddiqui A, et al. Carotid stenosis and stroke: medicines, stents, surgery – “wait-and-see” or protect? *Thromb Haemost* 2024 [in press].
4. Bonati LH, Jongen LM, Haller S, et al. New ischaemic brain lesions on MRI after stenting or endarterectomy for symptomatic carotid stenosis: a substudy of the International Carotid Stenting Study (ICSS). *Lancet Neurol* 2010; 9: 353-62.
5. Musialek P, de Donato G. Carotid artery revascularization using the endovascular route. In: *Peripheral Interventions – Practical Guide*. Edizioni Minerva Medica, Turin 2023; 142-72.
6. de Waard DD, Halliday A, de Borst GJ, et al. Choices of stent and cerebral protection in the ongoing ACST-2 trial: a descriptive study. *Eur J Vasc Endovasc Surg* 2017; 53: 617-25.
7. Musialek P. Proximal embolic protection with the Mo.Ma ultra device: a “must know how” for competent carotid artery stenting. *Endovasc Today* 2024; 23: 30-2.
8. Nikas D, Reith W, Schmidt A, et al. Prospective, multicenter European study of the GORE flow reversal system for providing neuroprotection during carotid artery stenting. *Catheter Cardiovasc Interv* 2012; 80: 1060-8.
9. Trystula M, Musialek P. Transient flow reversal combined with sustained embolic prevention in transcervical revascularization of symptomatic and highly-emboligenic carotid stenoses for optimized endovascular lumen reconstruction and improved peri- and post-procedural outcomes. *Adv Interv Cardiol* 2020; 16: 495-506.
10. Trystula M, Van Herzele I, Kolvenbach R, et al. Next-generation transcarotid artery revascularization: TransCarotid fLOW Reversal Cerebral Protection And CGUARD MicroNET-Covered Embolic Prevention Stent System To Reduce Strokes – TOPGUARD Study. *J Cardiovasc Surg* 2024 [in press]
11. Lehmann MF, Musialek P. MicroNET-covered stent use to seal carotid artery perforation. *Adv Interv Cardiol* 2023; 19: 284-8.
12. Tekieli L, Mazurek A, Pieniazek P, et al. Symptomatic atherosclerotic plaque progression in a first-generation carotid stent: management and 5-year clinical and imaging outcome – a case report. *Eur Heart J Case Rep* 2021; 6: ytab489.
13. Musialek P, Capoccia L, Alvarez CA, et al. Carotid artery endovascular reconstruction using micronet-covered stents in patients with symptoms or signs of cerebral ischemia (CGuard OPTIMA Trial Investigators; OPTimal sequestration of high-risk carotid lesions with effective lumen reconstruction using MicroNet-covered stents And the endovascular route, NCT04234854). TCT Featured Research [Internet]. Available from: <https://d18mqtx-krjsjgmh.cloudfront.net/public/2022-09/a355a7ab-6d71-44de-8ecf-6712bd763300.pdf> (accessed 21.05.2024).
14. Karpenko A, Bugurov S, Ignatenko P, et al. Randomized controlled trial of conventional versus MicroNet-covered stent in carotid artery revascularization. *JACC Cardiovasc Interv* 2021; 14: 2377-87.
15. Musialek P, Langhoff R, Stefanini M, et al. Carotid stent as cerebral protector: the arrival of Godot. *J Cardiovasc Surg* 2023; 64: 555-60.